BioPorto A/S (CPH: BIOPOR), an in-vitro diagnostics company, announced on Friday that it has entered into a global distribution agreement with Roche (VTX:ROG), under which BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche's cobas c 501/c 502 analysers.
Under the terms of the agreement, Roche will have worldwide exclusive distribution rights for the NGAL test adapted for use on Roche's cobas c 501/c 502 systems.
The company said this agreement has significant strategic importance to ensure the expanded availability of NGAL tests, as well as enhancing the awareness of NGAL as a diagnostic marker for acute kidney injury.
BioPorto expects the agreement to generate revenues starting in 2019.
The NGAL Test is CE marked and BioPorto is currently conducting clinical studies to generate data for FDA approval, which is expected later this year.
BioPorto Diagnostics provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma